New drug duo aims to tame Tough-to-Treat lymphomas
NCT ID NCT06484920
Summary
This study is testing whether combining two existing drugs—pembrolizumab and ATRA—can help control Hodgkin lymphoma or B-cell non-Hodgkin lymphoma that has returned or stopped responding to other treatments. It will enroll about 24 adults to see if the combination is safe and can shrink tumors. Researchers will also check if the treatment reduces certain immune cells that might be helping the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sidney and Lois Eskenazi Hospital
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.